(A) 2460 Pten;Braf melanoma cells were treated with the indicated doses of vemurafenib, PIK-90, or DMSO overnight. Whole-cell lysates were immunoblotted with the indicated antibodies. (B) Representative photomicrographs of 2130 and 2460 Pten;Braf melanoma cells, which have invaded through Matrigel chambers under hypoxia or normoxia. Original magnification, ×10. (C) Quantification of 2130 and 2460 Pten;Braf melanoma cells, which have invaded through Matrigel chambers. (D) 2130 and 2460 Pten;Braf melanoma cells were transfected with siRNAs against murine Hif1α or Hif2α and immunoblotted with the indicated antibodies. (E) Representative photomicrographs of 2130 and 2460 Pten;Braf melanoma cells that were transfected with siRNAs against murine Hif1α or Hif2α and allowed to invade through Matrigel chambers under hypoxia. Original magnification, ×10. (F) Quantification of 2130 and 2460 Pten;Braf melanoma cells that were transfected with siRNAs against murine Hif1α or Hif2α and allowed to invade through Matrigel chambers under hypoxia. Error bars show SEM. ***P < 0.0005;**P < 0.005; *P < 0.05.